Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs

Veterinary and Comparative Oncology

Volumn 7, Issue 1, 2009, Pages 38-45

  Northrup, N C ^a   Gieger, T L ^a,b   Kosarek, C E ^a   Saba, C F ^a   Leroy, B E ^a   Wall, T M ^a,c   Hume, K R ^a,d   Childress, M O ^a,e   Keys, D A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c Upstate Veterinary Specialists   (United States)

^d Department of Obstetrics Gynecology   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

Canine; Chemotherapy; Lymphosarcoma; Rescue

Indexed keywords

CANIS FAMILIARIS;

EID: 65349193301     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00170.x     Document Type: Article

References (14)

1. Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS and Mooney SC. MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989-2000). Journal of Veterinary Internal Medicine 2002; 16: 576-580.
2. Rowinsky EK. Antimicrotubule agents. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, 4th edn., BA Chabner and DL Longo, eds., Philadelphia, Lippincott Williams, and Wilkins, 2006: 245-246.
3. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB and Mayer LD. Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats, and dogs. Anticancer Drugs 1994; 5: 579-590.
4. Veterinary Co-operative Oncology Group - common terminology criteria for adverse events (VCOG CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
5. Garrett LD, Thamm DH, Chun R, Dudley R and Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002; 16: 704-709.
6. Petrie A and Watson P. Experimental design and clinical trials. In: Statistics for Veterinary and Animal Science, A Petrie and P Watson, eds., Oxford, Blackwell Publishing, 1999: 57.
7. Hodgson DC and Tannock IF. Guide to studies of diagnostic tests, prognostic factors, and treatments. In: The Basic Science of Oncology, 4th edn., IF Tannock, RP Hill, RG Bristow and L Harrington, eds., New York, McGraw-Hill, 2005: 497.
8. Flory AB, Rassnick KM, Al-Sarraf R, Bailey DB, Balkman CE, Kiselow MA and Autio K. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine 2008; 22: 164-171.
9. Dervisis NG, Dominguez PA, Sarbu L, Newman RG, Cadile CD, Swanson CN and Kitchell BE. Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. Journal of the American Veterinary Medical Association 2007; 231: 563-569.
10. LeBlanc AK, Mauldin GE, Milner RJ, Mauldin GE, Milner RJ, LaDue TA, Mauldin GN and Bartges JW. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Veterinary and Comparative Oncology 2006; 4: 21-32.
11. Moore AS, London CA, Wood CA, William LE, Cotter SM, L'Heureux DA and Frimberger AE. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine 1999; 13: 395-398.
12. Vail DM and Young KM. Hematopoietic tumors. In: Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed., SJ Withrow and DM Vail, eds., St. Louis, Saunders Elsevier 2007: 717.
13. Ponce F, Magnol J, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K and Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. The Veterinary Journal 167: 2004: 158-166.
14. Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF and MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. Journal of the American Veterinary Medical Association 1994; 205: 1722-1728.